Compare MIND & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | VANI |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 95.8M |
| IPO Year | N/A | 2014 |
| Metric | MIND | VANI |
|---|---|---|
| Price | $7.62 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 155.8K | ★ 189.8K |
| Earning Date | 04-21-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.45 | $0.91 |
| 52 Week High | $14.50 | $1.92 |
| Indicator | MIND | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 26.88 |
| Support Level | $7.61 | N/A |
| Resistance Level | $9.26 | $1.26 |
| Average True Range (ATR) | 0.69 | 0.07 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 1.21 | 3.74 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.